Elevated inflammatory type 2 biomarkers at baseline predict multicomponent clinical remission following dupilumab treatment in patients with moderate-to-severe asthma
De Llano L, Guilleminault L, Canonica G, Pavord I, Couillard S, Porsbjerg C, Brusselle G, Castro M, Bourdin A, Altincatal A, Kwah J, Ledanois O. Elevated inflammatory type 2 biomarkers at baseline predict multicomponent clinical remission following dupilumab treatment in patients with moderate-to-severe asthma. Revue Française D'Allergologie Et D'Immunologie Clinique 2025, 65: 104323. DOI: 10.1016/j.reval.2025.104323.Peer-Reviewed Original ResearchModerate-to-severe asthmaClinical remissionDupilumab treatmentDrivers of type 2 inflammationType 2 biomarkersFractional exhaled nitric oxideOral corticosteroid useType 2 inflammationBaseline blood eosinophilsHuman monoclonal antibodyAdd-on dupilumabImprove lung functionExhaled Nitric OxidePost Hoc AnalysisPlacebo Q2WPlacebo recipientsBaseline FeNORemission rateCorticosteroid useDupilumabFeNO levelsRemissionBlood eosinophilsPlaceboLung function
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply